Drug intelligence / Profile preview

GD31

Development stage: Preclinical
Lead developer: Guangzhou Eighth People's Hospital
Administration: Intravenous

Overview

GD31 is an investigational drug currently under evaluation for the treatment of Novel Coronavirus Pneumonia (COVID-19). It is administered via intravenous drip. The specific mechanism of action and its modality have not been publicly disclosed in the provided clinical trial information or general search results. Clinical development for GD31 is being conducted by Guangzhou Eighth People's Hospital and the Department of science and technology of Guangdong Province.

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on GD31.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GD31.

Explore the full profile